Bisphosphonate-related osteonecrosis of the jaw: Diagnosis, prevention, and management

Annual Review of Medicine

Volumn 60, Issue , 2009, Pages 85-96

  Ruggiero, Salvatore L ^a,b,c   Mehrotra, Bhoomi ^c  

^a New York Center for Orthognathic and Maxillofacial Surgery   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Bone metastasis; Jaw necrosis; Osteomyelitis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; STEROID; ZOLEDRONIC ACID;

ANAMNESIS; BONE NECROSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DENTAL HEALTH; DENTAL SURGERY; DRUG EXPOSURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TOOTH INJURY; TREATMENT DURATION; TREATMENT OUTCOME;

DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS; RISK FACTORS;

EID: 67650759752     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.60.063007.134350     Document Type: Review

References (65)

1. Lerner U. 2006. Bone remodeling in postmenopausal osteoporosis. J. Dent. Res. 85:584-95
2. Roodman G. 2004. Mechanism of bone metastasis. N. Engl. J. Med. 350:1655-64
3. van Holten-Verzantvoort A, Kroon H, Bijvoet O. 1993. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:491-98
4. Hortobagyi G, Theriault R, Porter L. 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N. Engl. J. Med. 335:1785-92
5. Berensen J, Lichtenstein A, Porter L. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334:484-93
6. Hortobagyi G, Theriault R, Lipton A. 1998. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:2038-43
7. Berensen J, Lichtenstein A, Porter L. 1998. Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. 16:593-602
8. Theriault RL, Lipton A, Hortobagyi GN. 1999. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized placebo-controlled trial. J. Clin. Oncol. 17:846
9. Conte P, Coleman R. 2004. Bisphosphonates in the treatment of skeletal metastases. Sem. Oncol. 31:59-63
10. Michaelson M, Smith M. 2005. Bisphosphonates for the treatment and prevention of bone metastases. J. Clin. Oncol. 23:8219-24
11. Hillner B, Ingle J, Berenson J. 2000. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J. Clin. Oncol. 18:1378-91
12. Berenson J, Hillner B, Kyle R. 2002. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 20:3719-36
13. United States Food and Drug Administration Oncologic Drugs Advisory Committee. 2005. Combidex briefing information. http://www.fda.gov/ohrms/ dockets/ac/cder05.html
14. Chestnut C, Majumdar S, Gardner J. 2001. Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites. Adv. Exp. Med. Biol. 496:95-97
15. Guyatt G, Cranney A, Griffith L. 2002. Summary of meta-analysis of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol. Metab. Clin. North Am. 31:659-79
16. Black D, Cummings S, Karpf D. 1996. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-41
17. Hosking D, Chilvers C, Christiansen C. 1998. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med. 338:485-92
18. Ravin P, Bidstrup M,Wasnick R. 1999. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study randomized, controlled trial. Ann. Intern. Med. 131:935-42
19. McClung M, Geusens P, Miller P. 2001. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344:333-40
20. Miller P, Roux C, McClung M. 1999. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. Arthritis Rheum. 42:S287
21. Bilezikian J. 2006. Osteonecrosis of the jaw-Do bisphosphonates pose a risk? N. Engl. J. Med. 355:2278-81
22. Gibbs S, O'Grady J, Seymour J. 2005. Bisphosphonate-induced osteonecrosis of the jaws requires early detection and intervention. Med. J. Aust. 183:549-50
23. Greenberg M. 2004. Intravenous bisphosphonates and osteonecrosis (editorial). Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endond. 93:259-60
24. Marx R, Sawatari Y, Fortin M. 2005. Bisphosphonate-induced exposed bone (osteonecrosis\osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J. Oral Maxillofac. Surg. 63:1567-75
25. Mehrotra B, Fantasia J, Nissel-Horowitz S, Ruggiero S. 2003. Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy.Acase report. Proc. Am. Soc. Clin. Oncol. 22:795 (Abstr.)
26. Mehrotra B, Ruggiero S. 2005. Bisphosphonate related osteonecrosis (BRON) of the jaw: single institutional update. Blood 106:291 (Abstr.)
27. Melo M, Obeid G. 2005. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. J. Am. Dent. Assoc. 136:1675-81
28. Migliorati C, Schubert M, Petersen D. 2005. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer 104:83-93
29. Purcell P, Boyd I. 2005. Bisphosphonates and osteonecrosis of the jaw. Med. J. Aust. 182:417-18
30. Rosenberg T, Ruggiero S. 2003. Osteonecrosis of the jaws associated with the use of bisphosphonates. J. Oral Maxillofac. Surg. 61(Suppl. 1):60
31. Ruggiero S, Fantasia J, Carlson E. 2006. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endond. 102:433-41
32. Ruggiero S, Mehrotra B, Rosenberg T. 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62:527-34
33. Van Poznak C,Ward B. 2006. Osteonecrosis of the jaw. Curr. Opin. Orthoped. 17:1-7
34. Vannucchi A, Ficarra G, Antonioli E. 2005. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br. Hematol. 128:738-40
35. Wilkinson G, Kuo Y, Freeman J, Goodwin J. 2007. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaws: a population-based analysis. J. Natl. Cancer. Inst. 99:1016-24
36. Etminan M, Aminzadeh K, Matthew I, Brophy J. 2008. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J. Rheumatol. 35:1-5
37. American Association of Oral and Maxillofacial Surgeons. 2007. Position paper on bisphosphonate-related osteonecrosis of the jaw. J. Oral Maxillofac. Surg. 3:369-76
38. Mavrokokki T, Cheng A, Stein B, Goss A. 2007. The nature and incidence of bisphosphonate associated osteonecrosis of the jaws in Australia. J. Oral Maxillofac. Surg. 3:415-23
39. Allen M, Burr D. 2008. Mandible matrix necrosis in beagle dogs following 3 years of daily oral bisphosphonate treatment. J. Oral Maxillofac. Surg. 66:987-94
40. Landesberg R, Cozin M, Cremers S, et al. 2008. Inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral Maxillofac. Surg. 66:839-47
41. MacArthur H, Estilo C, Huryn J, et al. 2008. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J. Clin. Oncol. 26:652-55
42. Huja S, SA F, Hill J, et al. 2006. Remodelling dymanics in the alveolar process in skeletally mature dogs. Anat. Rec. Discov. Mol. Cell. Evol. Biol. 288:1243-49
43. Garetto L, Chen J, Parr J, et al. 1995. Remodeling dynamics of bone supporting rigidly fixed titanium implants: a histomorphometric comparison in four species including humans. Implant. Dent. 4:235-43
44. Goh S, Yang K, Koh J, et al. 2007. Subtrochanteric insufficiency fractures in patients on alendronate therapy. J. Bone Joint. Surg. 89-B:349-53
45. Lenart B, Lorich D, Lane J. 2008. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 358:1304-5
46. Cafro A, Barbarano L, Andriani A. 2005. Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: an Italian experience. Blood 106:5152 (Abstr.)
47. Dimopoulos M, Kastritis E, Moulopoulos L. 2005. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. Blood 106:637 (Abstr.)
48. Durie B, Katz M, Crowley J. 2005. Osteonecrosis of the jaw and bisphosphonates (letter). N. Engl. J. Med. 353:99
49. Gallucci C, Agrillo A, Iannetti G. 2005. Possible role of ozone therapy in the treatment of osteonecrosis of the jaw in multiple myeloma patients. Blood 106:3460 (Abstr.)
50. Pozzi S, Marcheselli R, Sacchi S. 2005. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. Blood 106:5057 (Abstr.)
51. Tosi P, Zamagni E, Cangini D. 2005. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid. Blood. 106:3461 (Abstr.)
52. Badros A, Weikel D, Salama A. 2006. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J. Clin. Oncol. 24:945-52
53. Woo S, Hellstein J, Kalmar J. 2006. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144:753-76
54. Hoff A, Toth B, Altundag K. 2006. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J. Clin. Oncol. 24:8528
55. Yarom N, Yahalom R, Shoshani Y, et al. 2007. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos. Int. 18:1363-70
56. Black D, Schwartz A, Ensrud K. 2006. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-38
57. Odvina C, Zerwekh J, Sudhaker R. 2005. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90:1294-301
58. Colon-Emeric C. 2006. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis. Enough of a good thing (editorial). JAMA 296:2968-69
59. Ott S. 2005. Long-term safety of bisphosphonates (editorial). J. Clin. Endocrinol. Metab. 90:1897-99
60. Lacy M, Dispenzieri A, Gertz M. 2006. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin. Proc. 81:1047-53
61. Khosla S, Burr D, Cauley J, et al. 2007. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society of Bone and Mineral Research. J. Bone Miner. Res. 22:1479-91
62. Bone H, Hosking D, Devogelaer J, et al. 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350:1189-99
63. Dimopoulos M, Kastritis E, Bamia C, et al. 2007. Decreased incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid after application of preventive measures. Blood. 110:1056A (Abstr.)
64. Badros A, Evangelos T, Goloubeva O, et al. 2007. Long-term follow-up of multiple myeloma patients with osteonecrosis of the jaw. Blood 110:1030A-31A (Abstr.)
65. Mehrotra B, Fantasia J, Ruggiero S. 2008. Outcomes of bisphosphonate related osteonecrosis of the jaw. Importance of staging and management guidelines. A large single institutional update. J. Clin. Oncol. 26 (Abstr.)